Inventory Of Fda-Approved Adc Drugs
The global ADC drug market will be approximately $5.2 billion by 2021
Apparatus
Disease
Long-Term Antihypertensive Drugs Hurt Liver And Kidneys? Doctors: No Medication Is More Risky!
Many elderly people have high blood pressure themselves, but refuse to stick to their antihypertensive medication, thinking that taking it for a long time will have many side effects.
Medical
Breast Cancer: a Brighter Future For Patients As New Cutting-Edge Drugs Continue To Emerge!
With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.
Apparatus
"New 'Breakthrough' Alzheimer's Drug Approved: Slows Brain Decline By 27%, But $26,500/Year Pricing Controversial
Eisai and Biogen have partnered to develop Leqembi and have priced it at $26,500 per year.
Apparatus
Nature Medicine publishes results of H-drug combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma
H-Drugs in the leading international journal again!
Apparatus
New Drug Expected For Patients With Low HER2 Expression, FDA Grants Priority Review Status To Enhertu
The FDA granted priority review status to Enhertu (DS-8201) for the treatment of patients with HR-positive, low HER2-expressing breast cancer, and Enhertu has enabled these patients to remain disease-free for an average of 10.1 months, with an average overall survival time of nearly two years. A decision on approval is expected to be made in the fourth quarter of this year.
Apparatus
Newly Approved Targeted Drug Makes 79% Of Patients' Tumours Disappear Altogether, This Type Of Blood Tumour Is Saved!
The US FDA has approved pemigatinib, the first targeted drug to date for patients with specific mutated blood tumours, and the results of the study show that the drug made tumours disappear completely in 79% of patients!
Apparatus
Two-Drug Combination For Refractory Thyroid Cancer, 100% Effective!
Data from a study presented at the annual meeting of the European Society of Medical Oncology in 2022 showed that lenvatinib in combination with Pembrolizumab could give 100% efficacy in this group of patients.
Apparatus
Two-Drug Combination For Specific Mutation Colorectal Cancer With 100% Efficiency!
A study at Massachusetts General Hospital in the US demonstrated that Adagrasib alone and in combination with cetuximab delivered good results in patients with advanced colorectal cancer with KRAS G12C mutations, with 46% of subjects experiencing substantial tumour shrinkage and an efficacy rate of 100%.
Apparatus
Another Cancer-Independent Targeted Drug Approved! Up To 84% Efficacy!
Targeted drug Selpercatinib has received accelerated approval from the FDA. It is cancer-independent and may benefit any solid tumour with a positive RET gene fusion. It is up to 84% effective in selected patients with non-small cell lung cancer!